During the last three months, 20 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 13 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 4 | 6 | 1 | 0 | 0 |
| 3M Ago | 2 | 4 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1199.6, along with a high estimate of $1300.00 and a low estimate of $1000.00. This current average reflects an increase of 6.13% from the previous average price target of $1130.35.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Raises | Outperform | $1282.00 | $1250.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1250.00 | $1250.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $1242.00 | $1166.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $1200.00 | $1150.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1240.00 | $1232.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $1300.00 | $1180.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $1200.00 | $1125.00 |
| Carter Gould | Barclays | Raises | Overweight | $1220.00 | $1200.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $1200.00 | $1135.00 |
| Tyler Van Buren | TD Cowen | Raises | Buy | $1200.00 | $1030.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Neutral | $1000.00 | $925.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $1166.00 | $1000.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $1180.00 | $1040.00 |
| Matthew Harrison | Morgan Stanley | Lowers | Overweight | $1182.00 | $1183.00 |
| Carter Gould | Barclays | Raises | Overweight | $1200.00 | $1050.00 |
| John Newman | Canaccord Genuity | Maintains | Buy | $1152.00 | $1152.00 |
| Jasper Hellweg | Argus Research | Raises | Buy | $1170.00 | $1060.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1229.00 | $1229.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $1150.00 | $1050.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1229.00 | $1200.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regeneron Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Regeneron Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
To gain a panoramic view of Regeneron Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
Get to Know Regeneron Pharmaceuticals Better
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Regeneron Pharmaceuticals: Delving into Financials
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Regeneron Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 12.32%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 40.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 5.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
